Impact of Baseline Central Retinal Thickness on Outcomes in the VIVID-DME and VISTA-DME Studies
Purpose. To report the impact of baseline central retinal thickness (CRT) on outcomes in patients with diabetic macular edema (DME) in VIVID-DME and VISTA-DME. Methods. Post hoc analyses of two randomized controlled trials in which 862 DME patients were randomized 1 : 1 : 1 to treatment with intravi...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2018/3640135 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832559069932552192 |
|---|---|
| author | Edoardo Midena Mark Gillies Todd A. Katz Carola Metzig Chengxing Lu Yuichiro Ogura |
| author_facet | Edoardo Midena Mark Gillies Todd A. Katz Carola Metzig Chengxing Lu Yuichiro Ogura |
| author_sort | Edoardo Midena |
| collection | DOAJ |
| description | Purpose. To report the impact of baseline central retinal thickness (CRT) on outcomes in patients with diabetic macular edema (DME) in VIVID-DME and VISTA-DME. Methods. Post hoc analyses of two randomized controlled trials in which 862 DME patients were randomized 1 : 1 : 1 to treatment with intravitreal aflibercept 2.0 mg every 4 weeks (2q4), intravitreal aflibercept 2.0 mg every 8 weeks after five initial monthly doses (2q8), or macular laser photocoagulation at baseline and as needed. We compared visual and anatomical outcomes in subgroups of patients with baseline CRT < 400 μm and ≥400 μm. Results. At weeks 52 and 100, outcomes with intravitreal aflibercept 2q4 and 2q8 were superior to those in laser control-treated patients regardless of baseline CRT. When looked at in a binary fashion, the treatment effect of intravitreal aflibercept versus laser was not significantly better in the ≥400 μm than the <400 μm group; when looked at as a continuous variable, baseline CRT seemed to have an impact on the treatment effect of intravitreal aflibercept versus laser. Conclusions. Post hoc analyses of VIVID-DME and VISTA-DME demonstrated the benefits of intravitreal aflibercept treatment in DME patients with baseline CRT < 400 μm and ≥400 μm. This trial is registered with NCT01331681 and NCT01363440. |
| format | Article |
| id | doaj-art-49f10e630ebc4907adbab54e4c2a2b2a |
| institution | Kabale University |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-49f10e630ebc4907adbab54e4c2a2b2a2025-02-03T01:30:58ZengWileyJournal of Ophthalmology2090-004X2090-00582018-01-01201810.1155/2018/36401353640135Impact of Baseline Central Retinal Thickness on Outcomes in the VIVID-DME and VISTA-DME StudiesEdoardo Midena0Mark Gillies1Todd A. Katz2Carola Metzig3Chengxing Lu4Yuichiro Ogura5Department of Ophthalmology, University of Padova, Padua, ItalySave Sight Institute, Sydney Medical School, University of Sydney, Sydney Eye Hospital, Sydney, NSW, AustraliaBayer US, LLC, Whippany, NJ, USABayer AG, Berlin, GermanyBayer US, LLC, Whippany, NJ, USADepartment of Ophthalmology & Visual Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, JapanPurpose. To report the impact of baseline central retinal thickness (CRT) on outcomes in patients with diabetic macular edema (DME) in VIVID-DME and VISTA-DME. Methods. Post hoc analyses of two randomized controlled trials in which 862 DME patients were randomized 1 : 1 : 1 to treatment with intravitreal aflibercept 2.0 mg every 4 weeks (2q4), intravitreal aflibercept 2.0 mg every 8 weeks after five initial monthly doses (2q8), or macular laser photocoagulation at baseline and as needed. We compared visual and anatomical outcomes in subgroups of patients with baseline CRT < 400 μm and ≥400 μm. Results. At weeks 52 and 100, outcomes with intravitreal aflibercept 2q4 and 2q8 were superior to those in laser control-treated patients regardless of baseline CRT. When looked at in a binary fashion, the treatment effect of intravitreal aflibercept versus laser was not significantly better in the ≥400 μm than the <400 μm group; when looked at as a continuous variable, baseline CRT seemed to have an impact on the treatment effect of intravitreal aflibercept versus laser. Conclusions. Post hoc analyses of VIVID-DME and VISTA-DME demonstrated the benefits of intravitreal aflibercept treatment in DME patients with baseline CRT < 400 μm and ≥400 μm. This trial is registered with NCT01331681 and NCT01363440.http://dx.doi.org/10.1155/2018/3640135 |
| spellingShingle | Edoardo Midena Mark Gillies Todd A. Katz Carola Metzig Chengxing Lu Yuichiro Ogura Impact of Baseline Central Retinal Thickness on Outcomes in the VIVID-DME and VISTA-DME Studies Journal of Ophthalmology |
| title | Impact of Baseline Central Retinal Thickness on Outcomes in the VIVID-DME and VISTA-DME Studies |
| title_full | Impact of Baseline Central Retinal Thickness on Outcomes in the VIVID-DME and VISTA-DME Studies |
| title_fullStr | Impact of Baseline Central Retinal Thickness on Outcomes in the VIVID-DME and VISTA-DME Studies |
| title_full_unstemmed | Impact of Baseline Central Retinal Thickness on Outcomes in the VIVID-DME and VISTA-DME Studies |
| title_short | Impact of Baseline Central Retinal Thickness on Outcomes in the VIVID-DME and VISTA-DME Studies |
| title_sort | impact of baseline central retinal thickness on outcomes in the vivid dme and vista dme studies |
| url | http://dx.doi.org/10.1155/2018/3640135 |
| work_keys_str_mv | AT edoardomidena impactofbaselinecentralretinalthicknessonoutcomesinthevividdmeandvistadmestudies AT markgillies impactofbaselinecentralretinalthicknessonoutcomesinthevividdmeandvistadmestudies AT toddakatz impactofbaselinecentralretinalthicknessonoutcomesinthevividdmeandvistadmestudies AT carolametzig impactofbaselinecentralretinalthicknessonoutcomesinthevividdmeandvistadmestudies AT chengxinglu impactofbaselinecentralretinalthicknessonoutcomesinthevividdmeandvistadmestudies AT yuichiroogura impactofbaselinecentralretinalthicknessonoutcomesinthevividdmeandvistadmestudies |